What are ANI Pharmaceuticals's profit margins?

ANI Pharmaceuticals (ANIP) runs a 60.8% gross margin and a 13.4% operating margin, with a 10.0% net margin.

Where do ANI Pharmaceuticals's ratios come from?

Every ratio is computed from ANI Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

ANI Pharmaceuticals ANIP Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Profitability
Gross margin	61.4%+2.1pp	59.3%-3.4pp	62.7%+6.6pp	56.1%+2.7pp
Operating margin	12.6%—	——	9.6%+21.4pp	-11.7%+6.7pp
Net margin	8.9%+11.9pp	-3%-6.9pp	3.9%+19.0pp	-15.1%+4.6pp
EBITDA margin	22.9%+14.3pp	8.6%-13.3pp	21.9%+15.7pp	6.3%+2.8pp
Free cash flow margin	19.4%+11.6pp	7.8%-14.8pp	22.6%+35.6pp	-13%—
Returns
Return on equity	16.6%+21.0pp	-4.4%-9.5pp	5%+19.8pp	-14.8%+1.3pp
Return on assets	5.7%+7.4pp	-1.7%-3.9pp	2.3%+8.5pp	-6.3%+0.7pp
Return on invested capital	15.7%+18.4pp	-2.7%-11.7pp	8.9%+15.9pp	-7%+2.0pp
Efficiency
Asset turnover	0.6×+0.1×	0.6×0.0×	0.6×+0.2×	0.4×+0.1×
Inventory turnover	2.4×+0.4×	2×+0.3×	1.7×+0.2×	1.5×+0.1×
Liquidity
Current ratio	2.7×0.0×	2.7×-0.9×	3.6×+0.1×	3.5×-0.2×
Quick ratio	2.2×+0.2×	2×-0.8×	2.8×+0.4×	2.4×-0.3×
Cash ratio	1×+0.3×	0.7×-0.8×	1.5×+1.0×	0.5×-0.7×
Leverage
Debt-to-equity	0.6×-0.2×	0.8×+0.1×	0.7×-0.2×	0.9×+0.1×
Debt-to-assets	0.2×0.0×	0.3×-0.1×	0.3×-0.1×	0.4×0.0×
Net debt / EBITDA	0.2×-3.2×	3.4×+2.7×	0.7×-11.2×	11.8×-12.7×
Per Share
Book value per share	$25.47+21.9%	$20.90-12.1%	$23.79+23.3%	$19.29-27.2%
Valuation
Market capitalization	$1.77B+52.6%	$1.16B+3.2%	$1.13B+60.4%	$702.17M-8.6%
Enterprise value	$1.81B+34.7%	$1.34B+12.1%	$1.2B+27.6%	$937.52M-1.5%
Price / earnings	22.6×—	——	60×—	——
Price / sales	2×+0.1×	1.9×-0.4×	2.3×+0.1×	2.2×-1.3×
Price / book	3.3×+0.4×	2.9×+0.3×	2.6×+0.4×	2.2×-0.1×
EV / EBITDA	8.9×-16.4×	25.4×+14.2×	11.2×-36.0×	47.2×-80.4×
EV / sales	2×-0.1×	2.2×-0.3×	2.5×-0.5×	3×-1.4×
Free cash flow yield	9.7%+5.6pp	4.1%-5.7pp	9.8%+15.6pp	-5.9%—
Earnings yield	4.4%+6.0pp	-1.6%-3.3pp	1.7%+8.5pp	-6.8%-1.3pp
Dividend yield	0.1%-0.1pp	0.1%0.0pp	0.1%-0.1pp	0.2%+0.2pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are ANI Pharmaceuticals's profit margins?: ANI Pharmaceuticals (ANIP) runs a 60.8% gross margin and a 13.4% operating margin, with a 10.0% net margin.
Where do ANI Pharmaceuticals's ratios come from?: Every ratio is computed from ANI Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.